Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.76 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.76 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.64 |
| ▸ | CFTR | P13569 | 1/20 | 0.63 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.59 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.58 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | ALPL | P05186 | 1/20 | 0.57 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29052513 | 0.97 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Theophylline Anhydrous SCHEMBL31213692 | 0.94 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL11293447 | 0.92 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL29528626 | 0.87 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Water SCHEMBL27884201 | 0.86 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL31337165 | 0.85 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Iodide SCHEMBL28973312 | 0.84 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7803025 | 0.84 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL28480801 | 0.83 | CFTR (0.62) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7276490 | 0.83 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342161-A1 | BISBENZYLISOQUINOLINES AS CONDITIONING AGENTS FOR IMMUNE THERAPY | Escend Pharmaceuticals, Inc. | 2024-10-17 | — | — | US | disclosed |
| US-20240307373-A1 | METHODS OF USE AND COMPOSITIONS OF BISBENZYLISOQUINOLINES FOR THE TREATMENT OF MALIGNANCIES | Escend Pharmaceuticals, Inc. | 2024-09-19 | — | — | US | disclosed |
| US-11951113-B2 | Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and a second polyphenolic compound | NEURALIA (FR) | 2024-04-09 | — | — | US | disclosed |
| EP-3592332-B1 | NOVEL VISCOELASTIC SOLUTION AND USE THEREOF IN RHUMATOLOGY | LABORATOIRE DE RHUMATOLOGIE APPLIQUEE (FR) | 2023-06-07 | — | — | EP | disclosed |
| EP-3801556-B1 | SYNERGESTIC COMBINATION COMPOSITION COMPRISING A STEROIDAL SAPONIN, A FIRST POLYPHENOLIC COMPOUND AND A SECOND POLYPHENOLIC COMPOUND | NEURALIA (FR) | 2022-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307373-A1 | METHODS OF USE AND COMPOSITIONS OF BISBENZYLISOQUINOLINES FOR THE TREATMENT OF MALIGNANCIES | MCL1, MYD88, BCL6B | PDE4A 422/4885PDE4B 283/4885PDE4C 742/4885 |
| US-20240342161-A1 | BISBENZYLISOQUINOLINES AS CONDITIONING AGENTS FOR IMMUNE THERAPY | NFATC1, CTNNB1, CAMK1D | PDE4A 2365/4885PDE4B 2628/4885PDE4C 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.